Recurrent Small Cell Lung Cancer (SCLC) Recruiting Phase 1 Trials for Topotecan (DB01030)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Small Cell Lung Cancer Recurrent / Refractory Small cell lung cancer / Recurrent Small Cell Lung Cancer / Recurrent Lung Small Cell Carcinoma / Recurrent Small Cell Lung Carcinoma

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05353439Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerTreatment